Literature DB >> 16606907

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

O Suchowersky1, S Reich, J Perlmutter, T Zesiewicz, G Gronseth, W J Weiner.   

Abstract

OBJECTIVE: To define key issues in the diagnosis of Parkinson disease (PD), to define features influencing progression, and to make evidence-based recommendations. Two clinical questions were identified: 1) Which clinical features and diagnostic modalities distinguish PD from other parkinsonian syndromes? 2) Which clinical features predict rate of disease progression?
METHODS: Systematic review of the literature was completed. Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence. RESULTS AND
CONCLUSIONS: 1. Early falls, poor response to levodopa, symmetry of motor manifestations, lack of tremor, and early autonomic dysfunction are probably useful in distinguishing other parkinsonian syndromes from Parkinson disease (PD). 2. Levodopa or apomorphine challenge and olfactory testing are probably useful in distinguishing PD from other parkinsonian syndromes. 3. Predictive factors for more rapid motor progression, nursing home placement, and shorter survival time include older age at onset of PD, associated comorbidities, presentation with rigidity and bradykinesia, and decreased dopamine responsiveness. Future research into methods for earlier and more accurate diagnosis of the disease and identification and clarification of predictive factors of rapid disease progression is warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16606907     DOI: 10.1212/01.wnl.0000215437.80053.d0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  67 in total

1.  Decade in review-movement disorders: tracking the pathogenesis of movement disorders.

Authors:  Oksana Suchowersky
Journal:  Nat Rev Neurol       Date:  2015-10-27       Impact factor: 42.937

Review 2.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

Review 3.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

4.  Clinical heterogeneity in newly diagnosed Parkinson's disease.

Authors:  Bart Post; Johannes D Speelman; Rob J de Haan
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

Review 5.  Parkinson's disease.

Authors:  C E Clarke
Journal:  BMJ       Date:  2007-09-01

6.  Combining testing methods.

Authors:  Uwe Walter; Tino Just
Journal:  Dtsch Arztebl Int       Date:  2013-05       Impact factor: 5.594

Review 7.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

8.  Cranial nerve I: olfaction.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2009-07

9.  Diagnostic test systematic reviews: bibliographic search filters ("Clinical Queries") for diagnostic accuracy studies perform well.

Authors:  Monika Kastner; Nancy L Wilczynski; Ann K McKibbon; Amit X Garg; R Brian Haynes
Journal:  J Clin Epidemiol       Date:  2009-02-20       Impact factor: 6.437

10.  Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial.

Authors:  Bahram Yousefi; Vahid Tadibi; Ali Fathollahzadeh Khoei; Ali Montazeri
Journal:  Trials       Date:  2009-08-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.